CC214-2 [CAS 1228012-18-7]

CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin -resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2].

[1228012-18-7]

C20H25N5O3

383.44

O=C1N=C2NC=C(C3=CC=C(C(C)(C)O)N=C3)N=C2N(CC4CCOCC4)C1

Autophagy; mTOR

MTORC1; mTORC2

98.41

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 70°C)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H302, H315, H319, H335

H302, H315, H319, H335